Aflutinib: all 57 studies that test it

Page 1 of 1. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.

• Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyNot yet recruitingNCT07878871Phase 2
• A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerNot yet recruitingNCT07661173Phase 2
• Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingNCT07655622Phase 1/2
• Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT07622706Phase 2
• Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II TrialNot yet recruitingNCT07517640Phase 2
• Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural EffusionNot yet recruitingNCT07482605Phase 2
• Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal MetastasisRecruitingNCT07348965Not applicable
• Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaRecruitingNCT07314216Phase 2
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesRecruitingNCT07304739Phase 2
• Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgNot yet recruitingNCT07298148Phase 2
• Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingNCT07193160Phase 2
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Phase 3
• A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Phase 1/2
• Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal MetastasesRecruitingNCT07092202Phase 4
• A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）RecruitingNCT07010419Phase 3
• A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruitingNCT06970639Phase 3
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical MutationsRecruitingNCT06674343Phase 3
• High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKIRecruitingNCT06652048Phase 2
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal MetastasisRecruitingNCT06643000Not applicable
• Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal MetastasesNot yet recruitingNCT06537297Phase 2
• Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
• High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With OsimertinibRecruitingNCT06394674Phase 2
• A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal MetastasisRecruitingNCT06339242Phase 2
• High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain MetastasesNot yet recruitingNCT06319950Phase 2
• To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT06192849Phase 2
• Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruitingNCT05987826Phase 2
• Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLCEnrolling by invitationNCT05813522Phase 2
• First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon MutationRecruitingNCT05548348Phase 2
• Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung CancerRecruitingNCT05445310Phase 2
• High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) MetastasesRecruitingNCT05379803Phase 2
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNARecruitingNCT05334277Phase 2
• Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingNCT05306132Phase 1
• Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
• To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT04853342Phase 3
• High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal MetastasisCompletedNCT06812871Phase 2
• Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedNCT05631678Phase 1
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Active, not recruitingNCT05607550Phase 3
• Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionActive, not recruitingNCT05466149Phase 2
• Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)CompletedNCT05465343Phase 2
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsActive, not recruitingNCT05364073Phase 1
• Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Status unknownNCT05255406Phase 2
• Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLCStatus unknownNCT05209256Phase 2/3
• Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaStatus unknownNCT05165355Phase 2
• ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung AdenocarcinomasStatus unknownNCT05079022Phase 1/2
• Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass OpacitiesStatus unknownNCT04982900Phase 2
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion MutationWithdrawnNCT04958967Phase 1
• Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCStatus unknownNCT04895930Phase 2
• Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion MutationCompletedNCT04858958Phase 1
• Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedNCT04360915Phase 1
• ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingNCT04143607Phase 3
• Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male VolunteersCompletedNCT03941340Phase 1
• Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male VolunteersCompletedNCT03926182Phase 1
• Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownNCT03502850Phase 1/2
• Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790MTerminatedNCT03452592Phase 2
• AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT03127449Not applicable
• Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung CancerTerminatedNCT02973763Phase 1

← Aflutinib overview